We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ciphergen, UCL, and UCL BioMedica Sign Collaboration Agreement
News

Ciphergen, UCL, and UCL BioMedica Sign Collaboration Agreement

Ciphergen, UCL, and UCL BioMedica Sign Collaboration Agreement
News

Ciphergen, UCL, and UCL BioMedica Sign Collaboration Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ciphergen, UCL, and UCL BioMedica Sign Collaboration Agreement "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ciphergen Biosystems, Inc. has announced that it has signed a research and license agreement with UCL (University College London) and UCL BioMedica Plc. to utilize Ciphergen's suite of proteomic solutions (Deep Proteome™, Pattern Track™ Process, and ProteinChip® System) to further their ongoing research in ovarian cancer.

The principal investigator, Professor Ian Jacobs of UCL and President of the European Society of Gynecological Oncology (ESGO), is recognized as a world authority on ovarian cancer.

He and his team manage the largest screening trial in the world - the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) which involves 200,000 women.

Ciphergen and its collaborators at UCL will work together to further validate and characterize ovarian cancer biomarkers as well as discover potential biomarkers.

They plan to utilize samples from a prospective collection of over 1000 patients with ovarian cancer, benign neoplasms and 4000 healthy controls recruited through 10 UK centres.

This work is expected to address multiple clinical questions, including validation of markers described in Cancer Research in August 2004, and the discovery of additional biomarkers that distinguish ovarian cancer from other gynecologic masses.

Under the terms of the agreement, Ciphergen will have exclusive rights to license discoveries made during the course of this collaboration.

“We are very excited to be working with Ciphergen. It is our belief that this technology could lead to breakthrough discoveries in the area of women's health,” said Professor Ian Jacobs.

“Combining Ciphergen's expertise in translational proteomics with our clinical resources and research expertise is an important step in our efforts to accelerate the development of new diagnostic approaches to ovarian and breast cancer.”

“Ciphergen is delighted to announce this agreement with University College London, a world renowned center of excellence for research into women's health,” said Gail Page, President and Chief Operating Officer of Ciphergen.

“Professor Ian Jacobs is a leading authority in the field and by joining forces with Professor Jacobs and his team, we are hopeful that our joint efforts will translate into improved diagnosis and treatment of these major life-threatening diseases.”

Advertisement